Clinical and economic effects of suboptimally controlled asthma

J. Lyle Bootman, William H. Crown, Allan T. Luskin

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Patients with difficult-to-treat or suboptimally controlled asthma consume a disproportionate share of asthma health care resources. Treatment strategies that minimize exacerbations may decrease the need for unscheduled medical services, reduce emergency department visits, and minimize asthma-related hospitalizations. Clinical trial evidence indicates the immunoglobulin-E blocker omalizumab reduces the frequency of asthma exacerbations, minimizes symptoms, and improves lung function in patients with moderate-to-severe asthma that is inadequately controlled by inhaled corticosteroid therapy. Treatment with omalizumab of patients with suboptimally controlled asthma may reduce the clinical and economic burden of asthma.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalManaged care interface
Issue number1
StatePublished - Jan 2004

ASJC Scopus subject areas

  • Health Policy


Dive into the research topics of 'Clinical and economic effects of suboptimally controlled asthma'. Together they form a unique fingerprint.

Cite this